<DOC>
	<DOCNO>NCT02131142</DOCNO>
	<brief_summary>The purpose study collect additional safety effectiveness data Biosensors BioFreedom™ BA9 Drug Coated Coronary Stent patient native , de novo coronary artery disease .</brief_summary>
	<brief_title>BioFreedom US IDE Feasibility Trial</brief_title>
	<detailed_description>This multi-center prospective trial 100 patient 15 center . The study population consist patient prevent symptomatic ischemic heart disease due de novo stenotic lesion ( ) native coronary artery ( y ) reference vessel diameter 2.25 mm 4.0 mm . The primary safety endpoint clinical trial occurrence major adverse cardiac event ( MACE ) define composite cardiac death , myocardial infarction , target lesion revascularization academic research consortium ( ARC ) definite stent thrombosis within 9 month follow implantation . The primary effectiveness endpoint trial in-stent late lumen loss 9 month compare historical control</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<criteria>Individual ≥ 18 year age Individual must clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , positive functional study ; Individual must acceptable candidate percutaneous coronary intervention ( PCI ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery Individual competent willing provide inform consent participate trial A know hypersensitivity contraindication aspirin , heparin , clopidogrel , sensitivity contrast medium adequately premedicated ; History know allergic reaction significant sensitivity drug similar BA9 ; A platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 ; A creatinine level &gt; 2.5 mg/dL ; Evidence acute myocardial infarction 72 hour intend stenting ( define : Q wave nonQ wave myocardial infarction Troponin either I T preprocedure elevate Institution 's upper limit normal ) ; Previous plan PCI vessel within 30 day pre post procedure ; Patient unable take clopidogrel 3 month patient comorbidities would prohibit cessation clopidogrel 3 month ; Planned adjunctive treatment intend stenting ( eg balloon valvuloplasty , percutaneous endovascular intervention , etc ) During intend index procedure target lesion ( ) require treatment device plain old balloon prior stent placement ( , limit , cut balloon , directional atherectomy , excimer laser , rotational atherectomy , thrombectomy , etc ) ; History document prior stroke within 6 month intend procedure ; Active peptic ulcer upper gastrointestinal bleeding document within prior 6 month ; History active bleeding diathesis coagulopathy refuse blood transfusion ; Individual pregnant , nurse planning pregnant ; Any previous plan treatment target vessel ( ) antirestenotic therapy include , limited brachytherapy ; Concurrent medical condition life expectancy le 12 month individual serious medical condition , opinion investigator , may adversely affect safety and/or effectiveness participant study ; Individual currently enrol another investigational drug device trial . If , however , investigational trial device drug become commercially available , trial consider investigational ; Previous ACS within 9 month pre post procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>ischemic heart disease</keyword>
	<keyword>CAD</keyword>
</DOC>